Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | UGT2B7 | P16662 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PPM1B | O75688 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4608110 | 0.81 | ALDH1A1 (0.42) | ALDH1A1LMNAUGT2B7KDM4ESMN1; SMN2 | |
| SCHEMBL4606378 | 0.81 | ALDH1A1 (0.42) | ALDH1A1LMNAUGT2B7KDM4ESMN1; SMN2 | |
| SCHEMBL4608105 | 0.81 | ALDH1A1 (0.42) | ALDH1A1LMNAUGT2B7KDM4ESMN1; SMN2 | |
| SCHEMBL812446 | 0.81 | ALDH1A1 (0.42) | ALDH1A1LMNAUGT2B7KDM4ESMN1; SMN2 | |
| SCHEMBL4606370 | 0.81 | ALDH1A1 (0.42) | ALDH1A1LMNAUGT2B7KDM4ESMN1; SMN2 | |
| SCHEMBL3984188 | 0.79 | ALDH1A1 (0.43) | ALDH1A1LMNAUGT2B7F10TP53 | |
| SCHEMBL3747168 | 0.78 | ALDH1A1 (0.46) | ALDH1A1LMNAKDM4ESMN1; SMN2PPM1B | |
| SCHEMBL3641631 | 0.78 | ALDH1A1 (0.46) | ALDH1A1LMNAKDM4ESMN1; SMN2PPM1B | |
| SCHEMBL3754080 | 0.78 | ALDH1A1 (0.46) | ALDH1A1LMNAKDM4ESMN1; SMN2PPM1B | |
| SCHEMBL3984138 | 0.76 | UGT2B7 (0.46) | UGT2B7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562575-B1 | FUSED CYCLOALKYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF I.A. EPILEPSY | ABBOTT LAB (US) | 2009-05-20 | — | — | EP | disclosed |
| US-20040209859-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES | 2004-10-21 | — | — | US | disclosed |
| US-20040077617-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209859-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | GRIN2A, GRIK1, GRIN2B | ALDH1A1 529/4885LMNA 1972/4885UGT2B7 1481/4885 |
| US-20040077617-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | GRIN2A, GRIK1, GRIN2B | ALDH1A1 529/4885LMNA 1972/4885UGT2B7 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.